Tolerability of combined modality therapy for rectal cancer in elderly patients aged 75 years and older
- PMID: 21377289
- DOI: 10.1016/j.ijrobp.2010.12.056
Tolerability of combined modality therapy for rectal cancer in elderly patients aged 75 years and older
Abstract
Purpose: To determine the rate of treatment deviations during combined modality therapy for rectal cancer in elderly patients aged 75 years and older.
Methods and materials: We reviewed the records of consecutively treated patients with rectal cancer aged 75 years and older treated with combined modality therapy at Massachusetts General Hospital and Brigham & Women's Hospital from 2002 to 2007. The primary endpoint was the rate of treatment deviation, defined as a treatment break, dose reduction, early discontinuation of therapy, or hospitalization during combined modality therapy. Patient comorbidity was rated using the validated Adult Comorbidity Evaluation 27 Test (ACE-27) comorbidity index. Fisher's exact test and the Mantel-Haenszel trend test were used to identify predictors of treatment tolerability.
Results: Thirty-six eligible patients had a median age of 79.0 years (range, 75-87 years); 53% (19/36) had no or mild comorbidity and 47% (17/36) had moderate or severe comorbidity. In all, 58% of patients (21/36) were treated with preoperative chemoradiotherapy (CRT) and 33% (12/36) with postoperative CRT. Although 92% patients (33/36) completed the planned radiotherapy (RT) dose, 25% (9/36) required an RT-treatment break, 11% (4/36) were hospitalized, and 33% (12/36) had a dose reduction, break, or discontinuation of concurrent chemotherapy. In all, 39% of patients (14/36) completed≥4 months of adjuvant chemotherapy, and 17% (6/36) completed therapy without a treatment deviation. More patients with no to mild comorbidity completed treatment than did patients with moderate to severe comorbidity (21% vs. 12%, p=0.66). The rate of deviation did not differ between patients who had preoperative or postoperative CRT (19% vs. 17%, p=1.0).
Conclusions: The majority of elderly patients with rectal cancer in this series required early termination of treatment, treatment interruptions, or dose reductions. These data suggest that further intensification of combined modality therapy for rectal cancer should be performed with caution in elderly patients, who require aggressive supportive care to complete treatment.
Copyright © 2011 Elsevier Inc. All rights reserved.
Similar articles
-
Outcomes and tolerability of chemoradiation therapy for pancreatic cancer patients aged 75 years or older.Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1171-7. doi: 10.1016/j.ijrobp.2009.06.020. Epub 2009 Sep 30. Int J Radiat Oncol Biol Phys. 2010. PMID: 19800182
-
Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1129-39. doi: 10.1016/j.ijrobp.2005.09.017. Epub 2006 Jan 18. Int J Radiat Oncol Biol Phys. 2006. PMID: 16414206 Clinical Trial.
-
Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: results from a randomized Phase III study.Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1017-24. doi: 10.1016/j.ijrobp.2010.07.007. Epub 2010 Oct 6. Int J Radiat Oncol Biol Phys. 2011. PMID: 20932687 Clinical Trial.
-
Can chemotherapy concomitantly delivered with radiotherapy improve survival of patients with resectable rectal cancer? A meta-analysis of literature data.Cancer Treat Rev. 2010 Nov;36(7):539-49. doi: 10.1016/j.ctrv.2010.03.002. Epub 2010 Mar 23. Cancer Treat Rev. 2010. PMID: 20334979 Review.
-
Adjuvant postoperative combined-modality therapy for rectal cancer.Oncology (Williston Park). 1999 Jul;13(7 Suppl 3):132-5. Oncology (Williston Park). 1999. PMID: 10442383 Review.
Cited by
-
Impact of preoperative chemotherapy on perioperative morbidity in combined resection of colon cancer and liver metastases.J Gastrointest Surg. 2023 Nov;27(11):2380-2387. doi: 10.1007/s11605-023-05758-x. Epub 2023 Jul 19. J Gastrointest Surg. 2023. PMID: 37468732
-
The Impact of Age in the Treatment of Non-comorbid Patients with Rectal Cancer: Survival Outcomes from the National Cancer Database.World J Surg. 2023 Aug;47(8):2023-2038. doi: 10.1007/s00268-023-07008-2. Epub 2023 Apr 25. World J Surg. 2023. PMID: 37097321
-
Variations in colorectal cancer pattern of care by age and comorbidity in South Australia.Cancer Med. 2023 Jun;12(11):12118-12127. doi: 10.1002/cam4.5901. Epub 2023 Apr 21. Cancer Med. 2023. PMID: 37084009 Free PMC article.
-
Toxicities and outcomes of neoadjuvant treatment in elderly patients with locally advanced rectal cancer: a scoping review protocol.BMJ Open. 2022 May 2;12(5):e061397. doi: 10.1136/bmjopen-2022-061397. BMJ Open. 2022. PMID: 35501084 Free PMC article.
-
Rectal cancer treatment and outcomes in elderly patients treated with curative intent.Mol Clin Oncol. 2021 Dec;15(6):256. doi: 10.3892/mco.2021.2418. Epub 2021 Oct 14. Mol Clin Oncol. 2021. PMID: 34712486 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous